|Bid||0.00 x 2900|
|Ask||0.00 x 900|
|Day's Range||18.20 - 19.17|
|52 Week Range||2.35 - 23.34|
|Beta (3Y Monthly)||0.61|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||33.20|
Amarin Corporation plc (AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, president and chief executive officer of Amarin, has been named EY’s Entrepreneur of The Year 2019 Award for Life Sciences in the New Jersey Region. “I am pleased that Amarin’s significant progress and innovative work is recognized by this award and thank the judges and our employees for this honor,” commented Mr. Thero. “This award reflects the high quality of Amarin’s employees and is a testament to our company’s accomplishments in addressing the enormous public health issue of cardiovascular disease.
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
BEDMINSTER, N.J. and DUBLIN, Ireland, June 18, 2019 -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of.
Meeting Coverage of 2019 Updated ADA Standards of Medical Care in Diabetes to Include Role of Icosapent Ethyl as a Management Option for Diabetic Patients with Cardiovascular.
Amarin Corporation plc's (NASDAQ:AMRN): Amarin Corporation plc, a pharmaceutical company, engages in the development...
BEDMINSTER, N.J. and DUBLIN, Ireland, June 04, 2019 -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of.
Stocks eked out a gain on Thursday, but it didn't feel like a victory for the bulls. "Gut" can only take you so far, but it feels like this market wants to go lower before it goes higher. Maybe that won't be the case and the tricky part is, one tweet from one person can change everything. Let's look at a few top stock trades. Top Stock Trades for Tomorrow 1: Dollar General Click to EnlargeWe heard from the dollar stores on Thursday, leading off with Dollar General (NYSE:DG). Shares are up 7% after beating earnings, but are running into possible resistance near $126.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIf prior resistance holds up, investors will want to see the 20-day and 50-day moving averages hold as support, even though that would discouragingly mean DG gives up most of its post-earnings gains. Below that is uptrend support currently near $119 and level support near $116.50. * 7 Stocks to Sell Amid an Escalating Trade War If resistance fails and DG goes higher, look to see it push up to channel resistance. Top Stock Trades for Tomorrow 2: Dollar Tree Click to EnlargeDollar Tree (NYSE:DLTR) also reported earnings and while shares jumped 3% on poor guidance (which is great!), the overall action is discouraging in my view. At least so far. Remember when we formulated a trade in DLTR around $100? Shares ran to almost $112 in very orderly fashion.However, it's since fallen apart. Now what?A rally above $100 was rejected on Thursday, so until it can clear this level, it's a no-touch for me. Ideally though, it will also clear short-term downtrend resistance (blue line) and the 20-day moving average.Below Thursday's low opens up a possible test of the 200-day. Top Stock Trades for Tomorrow 3: Apple Click to EnlargeApple (NASDAQ:AAPL) has been a dud lately, as investors worry about demand and tariff implications from the trade war. It tried to break out of a falling wedge pattern on Thursday, but failed to do so.Take careful note though, because the stock is sitting right above its 61.8% retracement at $175.20. A break below almost guarantees a test of $168 to $170 and possibly lower. A break over short-term resistance can run Apple back to the 200-day moving average. That is, assuming its 20-day doesn't act as resistance first. Top Stock Trades for Tomorrow 4: Veeva Systems Click to EnlargeLooking for a stud in a tough tape? How about Veeva Systems (NASDAQ:VEEV) after delivering a knockout quarter. VEEV hit its highest volume of the year on Thursday's 14% rally to new highs.Shares aren't overbought yet and momentum just turned in bulls' favor. Wow, that's saying a lot, isn't it?VEEV gave investors a little fakeout on Wednesday ahead of earnings, breaking below the 50-day before gapping higher on Thursday. It's now hitting channel resistance. VEEV has so much going for it on the chart, and that makes me think that maybe it can push through this trend.But if the overall market comes under pressure, VEEV stock may have no choice but to come down too. Follow the trends that have been in place so far this year. Above uptrend resistance and it's possible it can become a new floor of support for Veeva. Otherwise, prior trend is in play as support. A break of Wednesday's lows would signal big trouble, but that's a long ways off. Top Stock Trades for Tomorrow 5: Amarin Click to EnlargeAmarin (NASDAQ:AMRN) stock is coming off Wednesday's big rally, which gives investors a shot on the long side if they're so inclined.I wanted to look at this one yesterday, but thought I should give it one more day to see how it responds to Wednesday's big gain. I'm glad I did, because shares are down over 4% Thursday. As long as it holds up over prior downtrend resistance (blue line), AMRN is okay on the long side. * Ranking the Top 10 Stock Buybacks of Last Year It couldn't hold the 50-day, which would have been preferred, but over $17 and it's still okay. I would like AMRN on a slightly deeper dip, say down to $17.50 for a better risk/reward.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell was long AAPL. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Sell Amid an Escalating Trade War * 5 REITs to Buy While They're Dirt Cheap * The Only 3 Marijuana Stocks You Need to Own Compare Brokers The post 5 Top Stock Trades for Friday: AAPL, VEEV, DG, DLTR appeared first on InvestorPlace.
Amarin Corporation plc (AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that Gwen Fisher has joined the company in a newly created role as vice president of Corporate Communications. In this role, Fisher will be responsible for leading internal and external communications for the company. Specifically, she is charged with advancing and implementing an integrated, progressive corporate communications strategy designed to educate key stakeholders about the company and its lead product, Vascepa®.
Amarin stock jumped Wednesday after the Food and Drug Administration granted the biotech company's high triglyceride treatment priority review in preventing cardiovascular trouble.
Amarin shares surged after the company said the FDA agreed to an expedited review of its prescription-strength fish oil pill for patients at risk of heart attack or strokes. The FDA plans to review Vascep within six months instead of the usual 10, with a decision on approval expected sometime in late September. Amarin AMRN shares surged 15% in early afternoon trading Wednesday after the biopharmaceutical company said the Food and Drug Administration agreed to an expedited review of its prescription-strength fish oil pill for patients at risk of heart attack or strokes.
Amarin said Wednesday that its sNDA for Vascepa capsules — icosapent ethyl capsules, or a fish oil pill — has been accepted by the FDA with a Priority Review designation. Vascepa is poised to become the first drug indicated to reduce residual cardiovascular risk in patients with statin-managed LDL-C cholesterol, but persistently elevated triglycerides — an important indicator for cardiovascular disease.
BEDMINSTER, N.J. and DUBLIN, Ireland, May 29, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (AMRN) announced today that its supplemental new drug application (sNDA) for Vascepa® (icosapent ethyl) capsules has been accepted for filing and granted Priority Review designation by the U.S. Food and Drug Administration (FDA). The Prescription Drug User Fee Act (PDUFA) goal date assigned by the FDA for this sNDA is September 28, 2019. Assuming FDA approval, Vascepa will be the first drug indicated to reduce residual cardiovascular risk in patients with statin-managed LDL-C cholesterol, but persistent elevated triglycerides, an important indicator of cardiovascular disease.
Amarin or Iovance Biotherapeutics: Which Is a Better Pick in May?(Continued from Prior Part)Label expansionOn March 28, Amarin (AMRN) issued a press release announcing the submission of an sNDA (supplemental new drug application) to the FDA seeking
Amarin or Iovance Biotherapeutics: Which Is a Better Pick in May?(Continued from Prior Part)Vascepa demand in the first quarterIn the first quarter, Amarin (AMRN) reported net product sales of $72.7 million, a YoY rise of 66%. According to
Amarin or Iovance Biotherapeutics: Which Is a Better Pick in May?(Continued from Prior Part)Revenue guidanceIn its first-quarter earnings conference call, Amarin (AMRN) reiterated its fiscal 2019 net revenue guidance of $350 million, which
Amarin or Iovance Biotherapeutics: Which Is a Better Pick in May?Stock price movementsOn May 17, Amarin (AMRN) closed at $17.79, 2.30% higher than the previous close, 657.02% higher than the 52-week low of $2.35, and 23.76% lower than the 52-week
Amarin Corporation plc (AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that Vascepa® (icosapent ethyl) and its landmark cardiovascular outcomes trial, REDUCE-IT™ (Reduction of Cardiovascular Events With EPA - Intervention Trial), is scheduled to be featured prominently at the National Lipid Association (NLA) Scientific Sessions in Miami, May 16-19. One of three late-breaker sessions at this annual meeting, on Saturday, May 18, 4:40-4:50 p.m. ET, is devoted to an encore presentation of the unprecedented results of the REDUCE-IT cardiovascular outcomes study by Christie Ballantyne, MD, Vice Chair of Research at the Baylor College of Medicine.